![]() |
|
|
Vol. 13, Issue 8, 2853-2868, August 2002
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190
Submitted October 9, 2001; Revised March 29, 2002; Accepted May 21, 2002| |
ABSTRACT |
|---|
|
|
|---|
We recently purified the rat liver hyaluronan receptor for
endocytosis (HARE) and found abundant expression of 175- and ~300-kDa HARE species in sinusoidal endothelial cells of the liver,
spleen, and lymph nodes. We report herein the first cloning and
functional expression of the rat 175-kDa HARE. Peptide sequences were
obtained from the purified 175-kDa HARE, and degenerate oligonucleotide primers were designed for reverse transcription-polymerase chain reaction and cDNA cloning. Results of 5'-rapid amplification of cDNA
ends, Northern analysis, N-terminal sequence, and antibody reactivity
analyses indicated the absence of mRNA directly encoding the 175-kDa
HARE. This protein is most likely derived from a larger precursor.
Accordingly, we constructed an artificial 4.7-kb cDNA encoding the 1431 amino acid 175-kDa HARE. The predicted type I membrane protein has a
mass of 156,393 Da and a pI of 7.86. The 175-kDa HARE cDNA, fused to
the N-terminal leader sequence of the Ig
-chain, was transfected
transiently into COS-7 cells and stably into SK-Hep-1 cells,
respectively, to assess hyaluronan or hyaluronic acid (HA)-binding
activity and endocytosis. In both cases, HARE expression and HA-binding
activity were detected. Furthermore, stable SK-175HARE cells
demonstrated specific endocytosis of 125I-HA and receptor
recycling. Fluorescence-activated cell sorting analysis confirmed that
recombinant HARE was expressed on the cell surface and that fluorescent
HA uptake was inhibited by a specific blocking monoclonal antibody
against HARE. Additionally, HARE was substantially colocalized with
clathrin, but not with internalized HA that was delivered to lysosomes.
The results confirm that recombinant 175-kDa HARE is an authentic
endocytic receptor for HA and that this receptor can function
independently of the ~300-kDa HARE. HARE is the first functionally
identified member of a protein family that shares a similar
organization of Fasciclin, epidermal growth factor-like, Xlink, and
transmembrane domains.
| |
INTRODUCTION |
|---|
|
|
|---|
Hyaluronan or hyaluronic acid (HA) was discovered and named >68
years ago by Meyer and Palmer (1934)
and then shown by many other
investigators to be a common, ubiquitous component of essentially all
extracellular matrixes (ECMs) in vertebrates. HA is a linear polymer
composed of the repeating disaccharide unit 2-deoxy,
2-acetamido-D-glucopyranosyl-
(1,4)-D-glucuronopyranosyl-
(1,3). Although its structure is simple, HA influences many cell
functions and behaviors, including cell migration, differentiation, and phagocytosis (Laurent and Fraser, 1992
; Turley, 1992
; Knudson and
Knudson, 1993
; Toole, 1997
; Abatangelo and Weigel, 2000
). HA is an
important molecule in development (Gakunga et al., 1997
; Toole, 1997
), wound healing (Weigel et al., 1986
; Burd
et al., 1991
; Chen and Abatangelo, 1999
), angiogenesis (West
et al., 1985
; Deed et al., 1997
; Rahmanian
et al., 1997
), and tumor growth and metastasis (Csoka
et al., 1997
; Delpech et al., 1997
). The ability of HA to form large aggregates by binding to ECM proteoglycans, such as
aggrecan and perlecan, is necessary for normal tissue differentiation
(Vertel et al., 1994
; Handler et al., 1997
).
Previously, most investigators believed that the physiological function
of HA in the ECM was only structural or physical. However, HA is now
also recognized as a pharmacologically active signaling molecule.
Numerous cell types respond physiologically to HA of different sizes.
In particular, small, but not large, HA stimulates angiogenesis (West
et al., 1985
; Deed et al., 1997
; Rahmanian
et al., 1997
) and small, not large, HA stimulates activated macrophages to induce the expression of a large number of genes (Horton
et al., 1998
, 2000
).
The total body content of HA in a 70-kg human is roughly 15 g, and
the turnover of HA is up to 5 g/d (Laurent and Fraser, 1991
). HA and
chondroitin sulfate are components of the ECM in all vertebrate tissues
and are continuously synthesized and degraded in tissues throughout the
body. For example, ~50% of the body's total HA is in skin and this
HA has a metabolic half-life of <1.5 d (Tammi et al.,
1991
). There are fewer studies of chondrotin sulfate turnover, but this
is thought to occur in parallel with HA turnover via a similar, if not
identical mechanism. This makes physiological sense, because HA,
chondroitin sulfate, and other glycosaminoglycans are all released at
the same time from ECM after the cleavage of HA and proteoglycans,
especially aggregating proteoglycans associated with HA. In mammals,
sinusoidal liver endothelial cells (LECs) express a recycling endocytic
receptor that removes both HA and chondroitin sulfate from the
circulation by endocytosis via the clathrin-coated pit pathway (Raja
et al., 1988
; Smedsrod et al., 1988
; McGary
et al., 1989
; Laurent and Fraser, 1992
).
In previous studies to characterize the rat LEC HA receptor, we
identified two large membrane proteins of 175 and ~300 kDa that were
specifically labeled with a photoaffinity derivative of HA
(Yannariello-Brown et al., 1992a
) and that retained specific HA-binding activity in a novel ligand blot assay after SDS-PAGE (Yannariello-Brown et al., 1996
). We finally achieved the
first purification of these two putative HA receptors of 175 and ~300 kDa from isolated rat LECs using a specific monoclonal antibody (mAb)
against the 175-kDa protein (Zhou et al., 1999
). A major goal in the present study was to determine whether these two proteins are able to function independently as HA receptors or whether they must
both be present in a larger functional complex. We also demonstrated
previously that these HA receptors are expressed not only in rat liver
sinusoids but also in the venous sinuses of the red pulp in spleen and
the medullary sinuses of lymph nodes (Zhou et al., 2000
).
Because this receptor internalizes HA by the rapid coated pit-mediated
endocytosis pathway (Smedsrod et al., 1988
) and its tissue
distribution is not unique to liver, it was renamed hyaluronan receptor
for endocytosis (HARE).
Based on elegant studies by Laurent and Fraser (1992)
, we now
understand the basic mechanism for HA turnover in mammals, including humans. When [3H]HA is injected intravenously
into mice (Fraser et al., 1983
) or rabbits (Fraser et
al., 1981
), it is rapidly removed from the blood and concentrated
predominantly in liver, and to a lesser extent, in spleen and lymph
nodes. The present model of total body HA turnover in mammals is that
large native HA molecules (up to ~107 Da) in
the ECM are partially degraded to large fragments of
~106 Da that are released from the matrix into
lymphatic vessels and then flow to lymph nodes. The removal and
complete degradation of this HA and chondroitin sulfate then occurs via
clearance systems in different tissues that use the recently identified
HARE (Zhou et al., 1999
, 2000
). The first clearance site is
in the lymphatic system, particularly lymph nodes, which account for
~85% of HA and chondroitin sulfate turnover, and the second
clearance site is in the LECs of liver, accounting for ~15% of the
total body HA and chondroitin sulfate turnover. HARE in spleen
apparently accounts only for a small percentage of HA turnover.
Despite the turnover of up to 5 g of HA per day, the HA clearance
systems using HARE in lymph nodes and liver keep the normal steady-state concentration of HA in blood very low (i.e., 10-100 ng/ml). Clearance of the circulating HA from lymph and blood is likely
to be very important for normal health, because the viscosity of these
fluids could increase to dangerous levels if the concentration of HA
was allowed to increase, particularly if the HA was of high molecular
weight (i.e., >106) as found in lymph fluid.
Elevated serum HA levels are found in several disease conditions, such
as liver cirrhosis (Lai et al., 1998
; Yamada et
al., 1998
), rheumatoid arthritis (Manicourt et al.,
1999
), scleroderma (Freitas et al., 1996
), psoriasis (Lundin et al., 1985
), and some cancers (Thylen et al.,
1999
).
In this study we used degenerate oligonucleotide primers, based on peptide sequences of the purified rat 175-kDa HARE, for reverse transcription-polymerase chain reaction (RT-PCR) analysis, cDNA library screening, and 5'-rapid amplification of cDNA ends (RACE) analysis, to clone and express for the first time a functional 175-kDa HARE.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Materials and Buffers
The original TA cloning kit, pTrcHis2-TOPO TA cloning kit, TOPO
XL PCR cloning kit, pcDNA3.1, pSecTag2 vector, and TOP10F' electrocompetent cells were from Invitrogen (Carlsbad, CA). TRIzol reagent, Platinum Taq DNA Polymerase High Fidelity,
Thermoscript RT-PCR System kit, G418, and trypsin were purchased from
Invitrogen. EndoFree Plasmid Maxi kit, QIAprep spin miniprep
kit, and QIAquick Gel Extraction kit were from QIAGEN (Valencia, CA).
QuikHyb Hybridization Solution, XL1-Blue MRF' Escherichia
coli supercompetent cells, pfuTurbo DNA polymerase,
TaqPlus Long PCR System,
ZAP Express vector, and random
primer labeling kit were from Stratagene (La Jolla, CA). Nitrocellulose
membranes (Protran 0.1 µm), polyvinylidene difluoride, and
nylon membrane filters (NYTRAN) were from Schleicher & Schuell (Keene,
NH). Marathon cDNA Amplification kit was from CLONTECH (Palo Alto, CA).
Digoxigenin High Prime Labeling and Detection kit, RNA molecular weight
marker, and FuGENE 6 transfection reagent were from Roche Applied
Science (Indianapolis, IN). Thermo Sequenase Radiolabeled Terminator
Cycle Sequencing kit was purchased from U.S. Biochemical (Cleveland,
OH). Enhanced avian RT-PCR kit was from Sigma-Aldrich (St. Louis, MO).
PolyATtract mRNA Isolation kit was from Promega (Madison, WI).
Restriction enzymes were purchased from MBI Fermentas (St. Leon-Rot,
Germany). Custom oligonucleotides were synthesized by The Great
American Gene Co (Ramona, CA). and are shown in Table
1. [32P]dCTP was
from Amersham Biosciences (Piscataway, NJ). Goat anti-mouse IgG (H+L)
conjugated to rhodamine red or Alexa-Fluor 488 was from Molecular
Probes (Eugene, OR). Custom antibodies to synthetic peptides were
prepared in sheep or goat by Bethyl Laboratories (Montgomery, TX).
125I-HA (~70 kDa) was prepared from
aminohexyl-HA derivatives, modified only at the reducing ends, as
described previously (Raja et al., 1984
). Fluorescent-HA
(fl-HA), which was prepared by reaction of aminohexyl-HA with the
succinimidyl ester of rhodamine green (Molecular Probes), was a
generous gift from Dr. Carl T. McGary (HealthEast Care Sys, St. Paul,
MN). Saline sodium citrate (SSC) contains 150 mM sodium chloride
and 15 mM sodium citrate, pH 7.0. Hanks' balanced salt solution was
prepared according to the Grand Island Biologicals formulation
(Invitrogen, New York, NY; formulation is online at
www.invitrogen.com).
|
Purification and Sequencing of HARE
Rat LEC HARE was purified from membrane extracts by affinity
chromatography with RCA-I agarose and then mAb-30 Sepharose as described previously (Zhou et al., 1999
). The purified
proteins were reduced, subjected to SDS-PAGE, and stained with
Coomassie blue. The 175-kDa HARE protein band was excised and sent to
Dr. William Lane (Harvard Microchemistry Facility, Cambridge, MA) for
internal peptide sequence analysis after trypsin digestion. Additionally, the 175-kDa protein was partially purified by
two-dimensional electrophoresis (isoelectric focusing followed by
SDS-PAGE), and the appropriate protein zones were sent to the
Rockefeller University Microchemistry Facility for internal
sequence analysis of tryptic peptides. N-Terminal sequence analysis of
immunoaffinity-purified 175-kDa HARE was performed by Dr. Ken W. Jackson (Molecular Biology Resource Facility, William K. Warren Medical
Research Institute, University of Oklahoma Health Sciences Center,
Oklahoma City, OK). The resulting amino acid sequences of peptides
(Table 1) obtained by the Harvard Facility (GT-68, GT-81, GT-123,
GT-139, and GT-208) and the Rockefeller University Facility (peptides 1, 3, and 5) were used to design degenerate oligonucleotide primers for
RT-PCR analysis and to confirm isolation of the correct cDNA.
RT-PCR Analysis
Total RNA from isolated rat LECs was prepared using TRIzol reagent, and the mRNA was isolated from total RNA by using a polyATtract mRNA Isolation kit following the manufacturers' recommended protocols. First-strand cDNA was synthesized using the Thermoscript RT-PCR system from Invitrogen with random hexameric oligonucleotides or oligo(dT)20. The PCR reactions were carried out with incubation at 94°C for 2 min; 30 cycles of 45°C for 30 s, 72°C for 6 min, and 94°C for 30 s; and one cycle of 45°C for 30 s and 72°C for 15 min with degenerate oligonucleotide primers (Table 1) based on a particular unique peptide sequence. The PCR products were cloned into pCR2.1 or pTrcHis2 expression vector by using TA cloning kits from Invitrogen.
cDNA Library Screening
An endothelial cell cDNA expression library was prepared from
LEC mRNA in
ZAP Express by Stratagene. Approximately 2.4 × 105 plaque-forming units were screened with two
digoxigenin-labeled cloned RT-PCR products produced with primer pair
208F-123R (370 base pairs) and 123F-81R (1500 base pairs). All
screening was performed on duplicate nitrocellulose filters. The
nitrocellulose membranes were denatured in 1.5 M NaCl, 0.5 M NaOH for 2 min, neutralized in 1.5 M NaCl, 0.5 M Tris, pH 8.0, for 5 min, rinsed with 0.2 M Tris, pH 7.5, in 2× SSC for 30 s, and then baked at 80°C for 1 h. After prehybridization at 45°C for 30 min in
QuikHyb Hybridization Solution, the membranes were allowed to hybridize overnight at 45°C with a mixture of the two digoxigenin-labeled probes. The membranes were then washed twice in SSC containing 0.05%
SDS at room temperature, followed by two washes in 0.1× SSC containing
0.1% SDS at 45°C. The positive
ZAP-Express bacteriophage was
identified and purified, and the cloned DNA inserts were excised in
vivo into PBK-CMV phagemid by using ExAssist helper phage and XLOLR
bacterial cells as recommended in the manufacturer's manual. The
phagemid DNAs were purified and the inserts were sequenced.
Northern Blot Analysis
Total RNA and mRNA were isolated from rat LECs as described
above. RNA (20 µg/lane) or mRNA (1 µg/lane) samples in 20 mM
morpholinopropanesulfonic acid, 5 mM sodium acetate, pH 7.0, and 1 mM
EDTA, containing 6% (vol/vol) formaldehyde and 50% (vol/vol)
formamide were heated to 65°C for 5 min, placed immediately on ice,
and then electrophoresed on a 0.8% agarose gel in 20 mM
morpholinopropanesulfonic acid, 5 mM sodium acetate, pH 7.0, 1 mM EDTA,
and 2% (vol/vol) formaldehyde. The RNA was transferred overnight to
nylon membranes by the capillary method by using 5× SSC. The membranes
were treated as described above and then hybridized at 45°C with
three 32P-labeled DNA probes, prepared by the
random primer extension method (Taylor et al., 1976
). The
probes were made from the inserts of clones 5'-RACE#11 (1108 base
pairs), ZAP1P3 (1216 base pairs), and ZAP9P3 (1979 base pairs) and were
located at the 5' end, the middle, and the 3' end of the 175-kDa HARE
nucleotide sequence, respectively (Figure
1).
|
5'-RACE Analysis
The 5' end of the 175-kDa HARE cDNA was obtained using a
Marathon cDNA amplification kit from CLONTECH for 5'-RACE analysis. A
gene-specific primer (GSP), oligonucleotide GSP-1R, was used for
first-strand cDNA synthesis. After second-strand cDNA synthesis by the
method of Gubler and Hoffman (1983)
, a library of adaptors (CLONTECH)
was ligated to the double-strand cDNA. DNAs were amplified by PCR with
adaptor-ligated double-strand cDNA as the template with primer GSP-2R
and the adaptor primer from the Marathon kit as the primer pair. PCR
conditions were as follows: 94°C for 2 min; 30 cycles of 45°C for
30 s, 72°C for 6 min, and 94°C for 30 s; and 1 cycle of
45°C for 30 s and 72°C for 15 min. The PCR products were then
cloned into pCR2.1 by using the TA cloning kit from Invitrogen, and
colonies were screened by PCR by using GSP-2R and the adaptor primer.
Plasmid DNAs from positive clones were purified with QIAprep spin
plasmid kits and the inserts were sequenced.
Construction of a 175-kDa HARE cDNA with an N-Terminal Ig
-Chain
Leader Sequence
An 1152-base pair 5' fragment of the 175-kDa HARE cDNA was
amplified by RT-PCR using pfuTurbo polymerase with
GSP-5F(EcoRI), which contains an EcoRI
restriction site and encodes the N-terminal seven amino acids of the
175-kDa protein, and GSP-1R(AsnI), which contains two silent
G
A mutations that create a AsnI restriction site. The PCR products were separated on a 1% agarose gel, and the
1.15-kb DNA band was excised and purified using a QIAquick kit. The DNA
was cloned into the pSecTag2 B vector, which contains a murine Ig
-chain leader sequence for protein secretion. The ligated plasmid
was electrotransformed into TOP10F' electrocompetent cells
(Invitrogen), amplified by bacterial growth, and purified with a
QIAprep spin miniprep kit. The NheI/AsnI fragment
of this plasmid, which contains the upstream leader sequence, was then excised and purified. An interior 2226-base pair fragment of the 175-kDa HARE cDNA sequence was amplified by RT-PCR by using
pfuTurbo DNA polymerase with GSP-1F(AsnI), which
contains a silent C
T mutation to create a AsnI
restriction site, and primer GSP-GT81R. The PCR products were separated
on a 1.0% agarose gel and the excised 2.2-kb DNA band was purified
using a QIAquick Gel Extraction kit and digested with AsnI
and Eco52I (there is a Eco52I site within the 3'
approximate one-third of the HARE sequence, starting at nucleotide
position 3329). The 1.5-kb insert from the ZAP9P3 clone, which contains
the 3' end of the 175-kDa HARE cDNA, including the polyA site, was
amplified, purified, and cut with Eco52I and XhoI
to give the third fragment, which contains 1378 base pairs. The three
purified fragments of HARE cDNA were then simultaneously ligated with
pcDNA3.1, which had been digested with NheI and
XhoI, at a molecular ratio of 2:1 (insert:vector). The
ligated DNA was electroporated into TOP10F' electrocompetent cells, and colonies were screened by PCR and restriction enzyme digestion to
identify full-length inserts. Plasmid DNA from positive clones was
amplified in TOP10F' bacteria and purified using endofree plasmid maxi
kits, and the complete inserts were sequenced. The resulting plasmid
containing the 4708-base pair cDNA encoding the 175-kDa HARE is
designated p175HARE-
.
Transient Expression of the 175-kDa HARE in COS-7 Cells
COS-7 cells were grown to ~80% confluence in 35-mm culture
dishes, by using DMEM containing 10% fetal calf serum,
L-glutamine, and 100 U each of penicillin/streptomycin, and
then transfected with the purified p175HARE-
DNA (2 µg) by using 6 µl of FuGENE 6. At 40 h posttransfection, the cells were
detached by treatment with 0.05% trypsin and 0.53 mM EDTA, collected,
and washed two times with phosphate-buffered saline (PBS). The cells
were extracted with Tris-buffered saline (TBS) containing 1% NP-40 and
analyzed by SDS-PAGE. HARE expression was assessed by Western analysis with anti-HARE mAbs (Zhou et al., 2000
), and expression of
active HARE was assessed by a ligand blot assay using
125I-HA (Yannariello-Brown et al.,
1996
; Zhou et al., 1999
).
Selection of Stable Tranfectants Expressing the 175-kDa HARE
SK-Hep-1 cells (American Type Culture Collection, Manassas, VA)
were transfected with the purified p175HARE-
DNA by using FuGENE 6 in 35-mm culture dishes. Twenty-four hours after transfection the cells
were transferred to 100-mm dishes and grown in DMEM containing 10%
fetal calf serum, L-glutamine, 100 U each of
penicillin/streptomycin, and 0.4 mg/ml G418 for selection. After 15-20
d, antibiotic-resistant individual colonies were isolated using cloning
rings and detached by treatment with 0.05% trypsin and 0.53 mM EDTA
for 5 min at room temperature. Collected cells were expanded in 12-well
plates to assess HARE protein expression and function by enzyme-linked immunosorbent assay, Western blot, and 125I-HA
binding assays. Cultures that were positive in these assays were
further purified by dilution cloning. Final clones are designated SK-175HARE-#.
Fluorescence-activated Cell Sorting (FACS) Analysis of 175-kDa HARE Expression
SK-175HARE cells were grown in tissue culture flasks until confluent, trypsinized, divided into 13- × 100-mm glass tubes, and incubated on ice for 1 h with TBS containing 1% bovine serum albumin (BSA) and 10% goat serum to block nonspecific binding sites. For the analysis of surface staining, the cells were then incubated with 1 µg/ml of the indicated mAbs on ice for 30 min with gentle agitation every ~5 min. The cells were washed twice at 4°C by centrifugation for 3 min, resuspensed in PBS, and incubated with 4 µg/ml Alexa 488-conjugated goat anti-mouse secondary antibody for 45 min on ice. After two washes in PBS, the cells were resuspended in PBS, filtered through a 37-µm mesh to remove aggregates, and analyzed on an FACScalibur cytometer (BD Biosciences, San Jose, CA). For the analysis of fl-HA uptake, the cells were first incubated at 37°C for 30 min with 50 µg/ml of the indicated IgG or 100 µg/ml nonlabeled HA before adding fl-HA to a final concentration of 1.0 µg/ml. The cells were then incubated another 90 min at 37°C, washed, trypsinized, filtered, and analyzed as described above. Viable cells (10,000/sample) were selected for analysis by using appropriate gating settings.
Confocal Fluorescence Microscopy
SK-175HARE-34 cells were grown in Lab-Tek II chamber slides
(Nalge-Nunc, Naperville, IL) to 75-80% confluence, washed in PBS, fixed on ice with 4% formaldehyde in PBS for 15 min, and washed in
PBS. The rest of the protocol was also performed on ice. Cells were
permeabilized with 0.1% Triton X-100 in PBS for 5 min and incubated in
10 mM HEPES pH 7.4, 150 mM NaCl, and 6.7 mM KCl containing 1.5%
(wt/vol) BSA. A mix of four anti-HARE mAbs (nos. 30, 154, 174, and 235)
at 1 µg/ml each and a rabbit anti-clathrin polyclonal antibody
(diluted 1:500; Santa Cruz Biotechnology, Santa Cruz, CA) in buffer
1/BSA (Yannariello-Brown et al. 1992a
) were incubated with the cells for 30 min. After washing in PBS, clathrin was detected
using goat anti-rabbit IgG conjugated to Alexa-Flour 488 (diluted 1:500
in buffer 1/BSA), and HARE was detected with rhodamine
red-X-labeled goat anti-mouse IgG (diluted 1:1000 in buffer1/BSA)
obtained from Molecular Probes. The secondary antibodies were incubated
for 15 min and then washed in PBS. Samples were mounted in Fluorsave
(Calbiochem, San Diego, CA), and fluorescence was detected using a TCS
NT laser confocal microscope (Leica, Deerfield, IL). Digital images
were recorded using the TCS software package (Leica). To assess HA and
lysosome colocalization, cells were incubated at 37°C with 1 µg/ml
fl-HA in minimal essential medium for 1.5 h. In some samples
specific uptake was assessed by adding 100 µg/ml unlabeled HA to the
medium containing fl-HA. The medium was then aspirated and the cells
were incubated for an additional 30 min at 37°C with Lysotracker
(Molecular Probes) diluted 1 × 106 in
minimal essential medium. The cells were then washed with PBS and fixed
as described above. In the HARE and lysosome colocalization studies,
after the cells were treated with Lysotracker they were fixed,
permeabilized, and HARE was detected using Alexa-Flour 488 goat
anti-mouse IgG (diluted 1:1000 in buffer 1/BSA) as described above.
General
Protein content was determined by the method of Bradford (1976)
by using BSA as a standard. SDS-PAGE was performed according to the
method of Laemmli (1970)
. Western blotting was performed as described
by Burnette (1981)
with minor modifications (Zhou et al.,
2000
). DNA sequencing was performed by the dideoxy nucleotide method
(Sanger et al., 1977
), either manually using the thermo sequenase radiolabeled terminator cycle sequencing kit or by the Department of Microbiology and Immunology Sequence Facility (University of Oklahoma Health Sciences Center) with automated DNA sequencers (model 377; Applied Biosystems, Foster City, CA; or ALF).
125I Radioactivity was measured using an
Auto-Gamma Counting System (Packard Instrument Company, Downers Grove,
IL). Digital images from confocal microscopy were processed in Excel or
PowerPoint (Microsoft, Redmond, WA). Other digital images obtained by
scanning blots or autoradiograms with a ScanMaker 9600 XL (MicroTek,
Redondo Beach, CA) were processed using Visioneer Paperport,
version 5.1, and then Corel Paint and Corel Draw, version 9.0.
| |
RESULTS |
|---|
|
|
|---|
Assembly of Rat 175-kDa HARE cDNA
Using a specific anti-175-kDa HARE mAb, we recently purified two
rat liver HARE species that may be functional isoreceptors for HA
(Yannariello-Brown et al., 1997
; Zhou et al.,
1999
, 2000
). The 175-kDa and ~300-kDa HARE proteins are each able to
bind 125I-HA in a ligand blot assay after
nonreducing SDS-PAGE and electrotransfer and are immunologically
related, because all mAbs raised against the 175-kDa HARE also
recognize the ~300-kDa HARE (Zhou et al., 2000
). The
175-kDa HARE contains only one protein, whereas the ~300-kDa HARE
contains three disulfide-bonded subunits of ~260, 230, and 97 kDa
(Zhou et al., 1999
). The 260- and 230-kDa subunits of the
~300-kDa HARE are both recognized by the panel of anti-175-kDa HARE
mAbs (Zhou et al., 2000
).
The immunoaffinity purified 175-kDa HARE was reduced, resolved by
SDS-PAGE, excised, and subjected to internal tryptic peptide analysis
(Table 1). Primers were designed based on amino acid sequences of the
resulting peptides and PCR fragments were generated, cloned, and used
as probes to screen a custom-made
-ZAP Express rat LEC cDNA library.
Overlapping clones of various types were then used to assemble a
partial cDNA (Figure 1) that encoded the peptides identified from
tryptic digests of the purified 175-kDa HARE (Table 1). To verify the
fidelity of key partial cDNA clones isolated from the library or by
RT-PCR, we confirmed that these clones resulted in the expression, in
transformed bacteria, of protein fragments that were recognized in
Western analysis by one or more of our eight mAbs against the 175-kDa
HARE (our unpublished data). For example, clones ZAP9P3 and ZAP4P3
showed reactive bands at 68 and 72 kDa, respectively, with mAb-159 and
mAb-174. The cDNA assembled from the various positive clones, however,
lacked 5'-upstream noncoding sequences, an initiating codon and a
leader sequence for appropriate membrane insertion. When this partial cDNA was extended further upstream by 5'-RACE analysis, the resulting in-frame coding region was longer than anticipated for a glycoprotein of 185 kDa, which is the size of the 175-kDa HARE when reduced (Zhou
et al., 1999
, 2000
).
The purified 175-kDa HARE is a broad, rather than well focused, band in
SDS-PAGE, suggesting that it contains species of heterogeneous size.
Although some size heterogeneity is expected because the two HARE
species are glycoproteins with
25 kDa of N-linked oligosaccharides (Zhou et al., 1999
), another reason could be that the
purified protein was either randomly or specifically cleaved by
proteases. To test this latter hypothesis we performed
NH2-terminal sequence analysis on the
affinity-purified 175-kDa HARE and discovered two distinct termini
corresponding to regions of the encoded deduced protein that were 122 amino acids apart (Table 1 and Figure 2). Previous NH2-terminal sequencing attempts, before
having the partial cDNA sequence, had not yielded interpretable data,
because the yields were relatively low and a unique sequence was not
obtained. The deduced protein sequence information, however, enabled us to identify a major and a minor NH2-terminal
sequence beginning at amino acid 1 (SLPSL... ) and 122 (VIHGL...
), respectively.
|
The above-mentioned results indicated that the 175-kDa HARE protein
could be derived by proteolytic processing and led us to consider the
possibility that there is no mRNA species directly encoding the
protein, but rather that it is encoded by a much larger mRNA for the
~300-kDa HARE, whose protein product is then proteolytically
processed to the 175-kDa HARE. Consistent with this interpretation,
Northern analysis, using mRNA from rat LECs and probes from either the
5' end, the middle, or the 3' end of the cDNA (Figure 2) revealed a
major ~10-kb band (Figure 3). We did
not observe a separate mRNA species in the range of ~6-8 kb, which
might be the expected size range of the 175-kDa HARE transcript if it
was encoded directly.
|
Domain Structure and Characteristics of the Deduced 175-kDa HARE
The cDNA sequence presented in Figure 2 encodes a 1431-amino acid
protein that starts with the Ser residue that was identified as the
major NH2 terminus. The deduced protein contains
all five internal tryptic peptide sequences derived from the purified
175-kDa HARE protein, as well as three additional internal peptides
obtained from a partially purified HARE preparation (Table 1). The
protein is predicted to be a type I membrane protein (Figure
4), with a large
NH2-terminal extracellular domain (1322-1324
residues depending on the particular prediction program used), a single transmembrane domain
(~L1323-A1343), and a
small COOH-terminal cytoplasmic domain (~88 amino acids). The exact
boundaries predicted for the transmembrane domain of HARE are somewhat
uncertain; they vary by two or three amino acids on both sides of the
predicted domain, depending on the algorithm used. For example, the
programs TMPred, TMHMM, and PSORTII, respectively, predict a
transmembrane domain between residues 1327-1347, 1325-1347, and
1327-1343. The predicted mass of the protein is 156,393 Da and the
predicted isoelectric point is pH 7.86. The ectodomain contains 15 typical putative N-glycosylation sites (excluding one N-P-S
sequon and three atypical N-X-C sites), and two cysteine-rich regions.
The extracellular domain has multiple motifs and subdomains with
homology to regions identified in other receptors and matrix molecules.
Multiple epidermal growth factor (EGF)-like,
IgH3, and Fasciclin
domains, as well as one delta serrate ligand domain are also organized
throughout the extracellular domain of the 175-kDa HARE. In addition, a
93-amino acid region near the membrane junction
(Gly1063-Tyr1155) is
homologous to the mammalian proteoglycan extracellular Xlink domain and
the HA-binding domain of the link protein (e.g., 40 and 35% identical,
respectively, to these domains in human CD44 and bovine aggrecan).
Thirteen potential HA-binding motifs of the
B-X7-B type, where B is Lys or Arg (Yang et
al. 1994
), are also present in the 175-kDa HARE ectodomain.
|
The 175-kDa HARE Is Derived from a Larger Protein
The mRNA, partial cDNA, amino acid sequence, and mAb reactivity
data are all consistent with the hypothesis that there is a precursor
relationship among the 260- and 230-kDa subunits of the 300-kDa HARE
and the 175-kDa HARE protein. To test this possibility, we examined the
reactivity of these three HARE proteins with two different polyclonal
anti-peptide antibodies. One antibody was raised against a sequence
within the rat 175-kDa protein shown in Figure 2
(PKCPLKSKGVKK773) and the other antibody was
raised against a 16-amino acid putative coding region
(TVLVPSRRAFEDMDQNK) that begins 107 amino acids upstream of the
SLP... sequence identified as the amino-terminal start of the
purified rat 175-kDa HARE. There was no prior information about whether
this putative protein region is expressed. However, if all three HARE
proteins are derived from a larger precursor, then our prediction was
that the former antibody should recognize all three proteins, whereas
the latter antibody would recognize only the two larger proteins but
not the 175-kDa protein. This was the result obtained (Figure
5), which strongly supports the conclusion that the 175-kDa HARE is indeed derived from one of the
larger HARE proteins of the 300-kDa HARE. Peptide mapping of the three
purified HARE proteins will ultimately be required to confirm this
conclusion.
|
Expression of a Functional HA Receptor for Endocytosis from the 175-kDa HARE cDNA
To verify that we have cloned a bone fide cDNA for the 175-kDa
HARE, we performed HA-binding and internalization studies by using
transfected COS-7 or SK-Hep-1 cells expressing the 175-kDa protein.
Because there is no natural mRNA directly coding for the 175-kDa HARE
protein, we constructed an artificial cDNA that encodes the open
reading frame (ORF) for the 175-kDa HARE fused at the 5' end to a short
region of the Ig
-light chain sequence containing a start codon and
a membrane insertion signal or leader sequence (Figure
6). Transient transfection of this cDNA
into COS-7 cells, yielded a protein of the expected size that was
recognized in Western blots by the specific anti-HARE mAbs and that
bound 125I-HA specifically in the ligand blot
assay (Figure 7).
|
|
We then used the same p175HARE-
vector to generate stable cell lines
expressing HARE after antibiotic selection of transfected SK-Hep-1
cells. This cell line was chosen because it does not express any
detectable endogenous HA receptors capable of specific 125I-HA binding or endocytosis, and does not show
reactivity with the anti-HARE mAbs in Western blots. Seven independent
clones were selected, all of which had essentially identical
characteristics with respect to 175-kDa HARE expression and function.
The recombinant 175-kDa HARE expressed by these cells and the purified
rat LEC protein were essentially identical in their ability to bind
125I-HA in the ligand blot assay (Figure
8). FACS analysis showed that the
recombinant HARE protein was present at the cell surface (Figure
9). Specific mAbs against the 175-kDa
HARE bound to cells expressing recombinant HARE, but not to SK-Hep-1
parental cells (our unpublished data) or cells transfected with vector
alone. The internalization of fl-HA by SK-175HARE cells was specific and was mediated by the recombinant 175-kDa HARE as judged by its
competition with an excess of unlabeled HA (Figure
10B), its inhibition by ~98% with
mAb-174 (Figure 10C), and the lack of fl-HA uptake by SK-Hep-1 cells or
cells transfected with vector alone (Figure 10A).
|
|
|
Confocal fluorescence microscopy was then used to assess the cellular
distribution of HARE and internalized HA in SK-175HARE cells (Figure
11). As expected for a recycling
receptor mediating endocytosis via coated pits, much of the cellular
clathrin was colocalized with HARE (Figure 11, A-C), whereas most of
the intracellular HARE staining was not present in clathrin-containing
compartments, which is typical for an endocytic, recycling receptor
(Mellman, 1996
). HARE was not targeted to lysosomes as a consequence of mediating HA uptake (Figure 11, D-F), although internalized HA was
delivered to lysosomes as assessed by its colocalization with the
Lysotracker dye (Figure 11, G-I). The internalization of fl-HA was
virtually eliminated by a large excess of unlabeled HA (Figure 11J). A
variety of controls showed no significant fluorescence, including
SK-175HARE cells treated with mouse (our unpublished data) or
rabbit IgG (Figure 11K), and SK-Hep-1 cells (our unpublished data) or
cells transfected with vector alone (Figure 11L) incubated with fl-HA.
|
All the stable cell lines expressing HARE were also able to mediate the
continuous endocytosis of 125I-HA at 37°C (our
unpublished data). HA uptake, assessed by competition with unlabeled
HA, was ~90% specific and the amount of HA uptake in ~10 h was
14-times the surface receptor content (i.e., the number of HA binding
sites per cell). HARE protein was not degraded during this period,
based on Western analysis, indicating that the recombinant 175-kDa HARE
is a recycling endocytic receptor. Preliminary results (Weigel, Zhou,
and Weigel, unpublished data) confirm that the internalized HA is
degraded after endocytosis mediated by the recombinant 175-kDa HARE. We
also assessed the sensitivity of 125I-HA uptake
to hyperosmolarity, because doubling the osmolarity of the medium by
the addition of sucrose disrupts clathrin recycling and coated pit
formation (Oka et al., 1989
) and blocks
90% of the
specific 125I-HA accumulation by LECs (McGary
et al., 1989
). Hyperosmolar treatment of SK-175HARE clones
36 and 27 inhibited their specific endocytosis of
125I-HA (37°C; 4 h) by 90 and 81%,
respectively. These above-mentioned results affirm that the 175-kDa
HARE is responsible for the observed specific HA binding and
internalization in the SK-175HARE transfectants and that endocytosis of
HA occurs via the coated pit pathway.
| |
DISCUSSION |
|---|
|
|
|---|
Because it is nonimmunogenic and has special viscoelastic and
rheological properties in solution, HA is used in many clinical applications, and its medical uses are growing rapidly. For example, high molecular weight HA preparations are routinely used in ophthalmic surgeries (Goa and Benfield, 1994
) and to treat patients with osteoarthritis or rheumatoid arthritis by intraarticular injection (Manek and Lane, 2000
; Rosier and O'Keefe, 2000
). Due to its use in
such a wide array of medical applications, it is important that we
understand the biological effects of exogenously administered HA and
how its turnover and clearance from the body is regulated. Clearance of
the endogenous circulating HA from lymph and blood is also likely to be
very important for normal health, because the viscosity of these fluids
would rapidly increase to dangerous levels if HA was allowed to
accumulate, particularly if it was of high molecular weight as found in
lymph fluid (>106). HARE is abundantly expressed
in the sinusoids of liver and lymphatic tissues (Zhou et
al., 2000
), which is a localization ideally suited for keeping the
level of systemic HA low.
Our results indicate that the native rat 175-kDa HARE protein is most
likely derived from the proteolytic processing of a larger protein in
LECs. Although this cannot be unequivocally proven until this larger
protein is identified and shown to generate the 175-kDa HARE species,
the following results indicate that the precursor protein is one of the
two large subunits of the ~300-kDa HARE (Zhou et al.,
1999
). First, the 260- and 230-kDa subunits of the ~300-kDa HARE are
immunologically related to the 175-kDa HARE, because they cross-react
with all mAbs against the 175-kDa HARE (Zhou et al., 2000
)
and with the anti-peptide antibody used herein (Figure 5). Second, the
175-kDa HARE does not have a unique N terminus (Table 1), indicating
that it is sensitive to one or more cellular proteases. Third, the mRNA
encoding the 175-kDa HARE is longer than expected for this size
protein. Fourth, our present partial cDNA for the HARE protein encodes
>200 amino acids upstream of the N-terminal Ser of the functional
175-kDa HARE. Finally, the two largest HARE proteins were reactive with an antibody against a predicted amino acid sequence upstream of the
cDNA region encoding the native 175-kDa HARE. The latter result, in
particular, strongly supports the proteolytic processing model. We
conclude that the 260-kDa subunit (or its precursor) is the initial
gene product, from which both the 230- and 175-kDa proteins are then
derived by proteolysis.
The 175-kDa HARE protein is a functional HA receptor when expressed from a synthetic cDNA. This recombinant 175-kDa HARE mediated HA endocytosis through the coated pit pathway in the absence of the ~300-kDa HARE complex. Although it is possible that the 175-kDa HARE might interact with other protein(s) in LECs to achieve an even more rapid internalization, this HARE is nonetheless an independent functional receptor. The two HARE species can, therefore, be viewed as structurally related HA isoreceptors. Two HA receptors (i.e., the 175- and ~300-kDa HARE proteins) may be necessary to mediate the efficient uptake and degradation of HA in mammals because of the broad molecular mass range of HA present in tissues throughout the body. The two receptors present in liver, spleen, and lymph node could have different preferences for the size of the HA with which they interact.
Based on the SMART program of Schultz et al. (1998)
, the
large extracellular domain of the 175-kDa HARE
(~S1-L1324) is predicted
to contain four Fasciclin-like domains, a delta serrate ligand domain,
a Link domain, and at least 11 EGF-like domains arranged in two
clusters. These two clusters, which are cysteine-rich, are separated by
a ~360 amino acid cysteine-poor region. The Fasciclin-like domains
are related to a family of three Fasciclins, which are Ig-like cell
adhesion molecules expressed on a subset of axons during neuronal
development in insects (Kose et al., 1997
). Among the
numerous EGF-like domains are laminin-like, Ca2+-binding, EGF-1, and EGF-2 domains. Previous
studies of HARE function in isolated rat LECs showed that HA binding
and endocytosis do not require Ca2+ or other
divalent cations (Yannariello-Brown et al., 1992b
). Most of
these EGF-like domains are only partial, but several have the pattern
of six cysteines needed for the typical organization and folding of
this domain (Selander-Sunnerhagen et al., 1992
).
The 93-residue Link domain is a good candidate for an HA-binding region
within the extracellular domain of HARE, but it is likely that
multiple, as yet unidentified, non-Link HA-binding domains are present
in HARE as well. Day, Jackson, and colleagues have investigated the
structural requirements for HA-binding activity of Link domains from
various HA-binding proteins (Bajorath et al., 1998
; Banerji
et al., 1998
; Kahmann et al., 2000
). Although each active Link domain engages HA by critical contacts with a distinct
set of amino acids that form a long pocket on the surface of the
protein, there are common residues or residues with comparable characteristics at equivalent positions in these HA-binding regions. Most of the proteins containing Link domains are in the ECM and can
form stable multivalent networks with HA through these Link interactions, even although the binding affinity for a single HA-Link
domain interaction is relatively weak. Because the efficient endocytic
clearance of HA requires a high-affinity interaction with HARE, we
expect that the extracellular domain of HARE will contain other
HA-binding regions (e.g., the multiple B-X7-B
motifs are potential HA-binding sites).
The cytoplasmic domain of HARE
(~Y1344-R1431) contains
many possible phosphorylation sites: two Tyr, nine Ser, two His, and 11 Thr residues, although only residues S1378,
S1392, T1354,
T1380, T1396, and
T1410 are predicted (by NetPhos 2.0) to be
phosphorylated. No PEST motifs for rapid degradation, or consensus
sequences for O-glycosylation by GlcNAc are present. As
expected, for an endocytic receptor, the cytoplasmic domain contains
several candidate motifs for targeting the protein to clathrin-coated
pits. The sequence YSYFRL1349, which is at the
junction between the predicted transmembrane and cytoplasmic domains,
contains an interesting overlapping combination of two
XXB motifs,
where
is either tyrosine or phenylalanine, X can be any amino acid
and B is a hydrophobic residue with a bulky side chain. Similar
overlapping motifs are responsible for coated pit targeting of the low
density lipoprotein (LDL), mannose, and cation-dependent mannose
6-phosphate receptors (Mellman, 1996
), all of which are recycling,
endocytic clearance receptors. In addition, a third candidate
XXB
motif is present at FQRF1359 and a dileucine
motif occurs at LL1370.
The domain organization of HARE is different from that of the other
well-characterized HA-binding proteins or HA receptors, including
intercellular adhesion molecule-1, RHAMM (CD168), CD44, TSG-6, Link
protein, and LYVE-1 (Banerji et al., 1999
; Abatangelo and
Weigel, 2000
). For example, HARE and LYVE-1, which is a CD44-family member, are unrelated except in their homologous Xlink domains. Although LYVE-1 is also found in LECs (Carreira et al.,
2001
), our preliminary results indicate that LYVE-1 and HARE are
distributed very differently within rat LECs. An earlier identification
of ICAM-1 as the endocytic HA receptor in LECs was later acknowledged to be an artifact (McCourt and Gustafson, 1997
). HARE is distinct from
all other cell surface HA receptors because it is an endocytic, recycling receptor that mediates the rapid and efficient endocytosis of
both HA and chondroitin sulfate via the clathrin-coated pit pathway.
Liver may also contain a scavenger receptor able to internalize HA
(McCourt et al., 1999
).
A BLAST search of the protein database found five related sequences
that share a high level of identity with the rat 175-kDa HARE (Figure
12). There are two subfamilies of
related proteins, all of which are human, each with a distinct pattern
of conserved sequences. The three deposited sequences most related to
HARE (CAB61358, BAB15793, and AAF82398) represent putative proteins of
unknown function, with no evidence that they are expressed. The latter
deduced protein was designated FELL, a CD44-like precursor, because it
contains Fasciclin, EGF-like, and Link domains. The remaining two
sequences (CAB61827 encoding stabilin-1 and BAA13377) are more related
to each other than to HARE and the three sequences noted above. The
BAA13377 mRNA sequence was found in endothelial cells, but expression
of the protein was not verified and possible HA-binding activity was
not determined (Tsifrina et al., 1999
). The critical
question of whether the other putative proteins are expressed and
whether they are able to bind HA, remains to be tested. Nonetheless, it
is clear that these putative HA-binding proteins are highly related to
the HARE protein reported herein.
|
In an ongoing study (Zhou, McGary, Weigel, Saxena, and Weigel,
unpublished data), we have affinity purified the human HARE proteins
and identified a partial human cDNA, represented in part by accession
number BAB15793, as the human HARE homolog. A striking feature of this
HARE family is that virtually all of the cysteine residues within the
predicted extracellular domains are absolutely conserved (Figure 12).
This suggests that the overall folding and organization of the
extracellular domains of these proteins are the same. In addition,
family members have the same overall domain organization including the
Xlink domain and a single predicted transmembrane region. Although the
cytoplasmic domains of the two HARE subfamilies are the most divergent
regions, the candidate
XXB domains for targeting to coated pits are,
nonetheless, highly conserved. Based on the overall similarities in
their extracellular and cytoplasmic domains, we suggest that these
proteins constitute a family of membrane-bound receptors, with the
175-kDa HARE as the prototype and first functionally identified member.
The members of this family may all be able to bind and internalize HA,
chondroitin sulfate, or even other glycosaminoglycans through the
clathrin-coated pit pathway.
A ~2.5-kb portion of the rat HARE ORF maps to a region of the mouse genome spanning ~190 kb, deposited as a putative gene of unknown expression or function. This mouse HARE gene (accession no. AC025501.3) contains numerous introns and short exons. Although the orientation and relative position of many HARE exons (assigned when the sequence was compiled) seem to be incorrect throughout this region, there is >90% identity between the mouse and rat nucleotide sequences over >2 kb of coding region. The complete gene may, therefore, be >500 kb. The present report is the first functional identification of the protein encoded by this gene. A candidate human HARE gene (Zhou, McGary, Weigel, Saxena, and Weigel, unpublished data), located on chromosome 12 (accession no. NT_024383.2), has a similar organization to the mouse gene.
We conclude that the rat 175-kDa HARE is a bone fide endocytic receptor for HA, capable of functioning independently of the ~300-kDa HARE. Although it is possible that the 175- and ~300-kDa HARE species could also function together as a large complex, it is apparently not necessary for these two HAREs to be present in the same cell to create a specific functional HA receptor. Therefore, the 175- and ~300-kDa HAREs are most likely independent isoreceptors for HA.
| |
ACKNOWLEDGMENTS |
|---|
We thank Drs. Judy Yannariello-Brown and Paul DeAngelis for helpful discussions, Leona Medved for help preparing the manuscript, Dr. Carl T. McGary for the fl-HA, and Anil Singh for the preparation of LECs and technical assistance. We gratefully acknowledge the assistance of Jim Henthorn and the Flow and Image Cytometry Laboratory supported by the Warren Medical Research Institute. Accession numbers for the nucleic acid and protein sequences reported herein are in the GenBank database under AY007370 and AAG13634, respectively. This research was supported by National Institute of General Medical Sciences grant GM-35978 from the National Institutes of Health.
| |
FOOTNOTES |
|---|
* Corresponding author. E-mail address: Paul-Weigel{at}OUHSC.edu.
DOI: 10.1091/mbc.02-03-0048.
| |
ABBREVIATIONS |
|---|
Abbreviations used: ECM, extracellular matrix; FACS, fluorescence-activated cell sorting; fl-HA, fluorescent-HA; GSP, gene-specific primer; HA, hyaluronic acid, hyaluronate, hyaluronan; HARE, hyaluronan receptor for endocytosis; LEC, liver endothelial cell; mAb, monoclonal antibody; ORF, open reading frame; PBS, phosphate-buffered saline; RT-PCR reverse transcription-polymerase chain reaction, SSC, saline sodium citrate; TBS, Tris-buffered saline.
| |
REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
E. N. Harris, B. A. Baggenstoss, and P. H. Weigel Rat and human HARE/stabilin-2 are clearance receptors for high- and low-molecular-weight heparins Am J Physiol Gastrointest Liver Physiol, June 1, 2009; 296(6): G1191 - G1199. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Pandey, E. N. Harris, J. A. Weigel, and P. H. Weigel The Cytoplasmic Domain of the Hyaluronan Receptor for Endocytosis (HARE) Contains Multiple Endocytic Motifs Targeting Coated Pit-mediated Internalization J. Biol. Chem., August 1, 2008; 283(31): 21453 - 21461. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. N. Harris, J. A. Weigel, and P. H. Weigel The Human Hyaluronan Receptor for Endocytosis (HARE/Stabilin-2) Is a Systemic Clearance Receptor for Heparin J. Biol. Chem., June 20, 2008; 283(25): 17341 - 17350. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Kyosseva, E. N. Harris, and P. H. Weigel The Hyaluronan Receptor for Endocytosis Mediates Hyaluronan-dependent Signal Transduction via Extracellular Signal-regulated Kinases J. Biol. Chem., May 30, 2008; 283(22): 15047 - 15055. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-Y. Jung, S.-Y. Park, and I.-S. Kim Stabilin-2 is involved in lymphocyte adhesion to the hepatic sinusoidal endothelium via the interaction with {alpha}M 2 integrin J. Leukoc. Biol., November 1, 2007; 82(5): 1156 - 1165. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. N. Harris, S. V. Kyosseva, J. A. Weigel, and P. H. Weigel Expression, Processing, and Glycosaminoglycan Binding Activity of the Recombinant Human 315-kDa Hyaluronic Acid Receptor for Endocytosis (HARE) J. Biol. Chem., February 2, 2007; 282(5): 2785 - 2797. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. W. Gale, R. Prevo, J. Espinosa, D. J. Ferguson, M. G. Dominguez, G. D. Yancopoulos, G. Thurston, and D. G. Jackson Normal Lymphatic Development and Function in Mice Deficient for the Lymphatic Hyaluronan Receptor LYVE-1 Mol. Cell. Biol., January 15, 2007; 27(2): 595 - 604. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-O. Nam, H.-W. Jeong, B.-H. Lee, R.-W. Park, and I.-S. Kim Regulation of Tumor Angiogenesis by Fastatin, the Fourth FAS1 Domain of {beta}ig-h3, via {alpha}v{beta}3 Integrin Cancer Res., May 15, 2005; 65(10): 4153 - 4161. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. N. Harris, J. A. Weigel, and P. H. Weigel Endocytic Function, Glycosaminoglycan Specificity, and Antibody Sensitivity of the Recombinant Human 190-kDa Hyaluronan Receptor for Endocytosis (HARE) J. Biol. Chem., August 27, 2004; 279(35): 36201 - 36209. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Weigel and P. H. Weigel Characterization of the Recombinant Rat 175-kDa Hyaluronan Receptor for Endocytosis (HARE) J. Biol. Chem., October 31, 2003; 278(44): 42802 - 42811. [Abstract] [Full Text] [PDF] |
||||
![]() |
Glyco-Forum Glycobiology, May 1, 2003; 13(5): 11G - 13G. [PDF] |
||||
![]() |
B. Zhou, C. T. McGary, J. A. Weigel, A. Saxena, and P. H. Weigel Purification and molecular identification of the human hyaluronan receptor for endocytosis Glycobiology, May 1, 2003; 13(5): 339 - 349. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. Weigel Letter to the Glyco-Forum: HARE raising Glycobiology, May 1, 2003; 13(5): 12G - 13G. [Full Text] [PDF] |
||||
![]() |
B. Smedsrod, S. Johansson, and S. Goerdt Letter to the Glyco-Forum: Shooting HARE Glycobiology, May 1, 2003; 13(5): 11G - 12G. [Full Text] [PDF] |
||||
![]() |
J. A. Weigel, R. C. Raymond, C. McGary, A. Singh, and P. H. Weigel A Blocking Antibody to the Hyaluronan Receptor for Endocytosis (HARE) Inhibits Hyaluronan Clearance by Perfused Liver J. Biol. Chem., March 7, 2003; 278(11): 9808 - 9812. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||